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 Abstract: The use of luminescent colloidal quantum dots in biological investigations has 
increased dramatically over the past several years due to their unique size-dependent optical 
properties and recent advances in biofunctionalization. In this review, we describe the meth-
ods for generating high-quality nanocrystals and report on current and potential uses of these 
versatile materials. Numerous examples are provided in several key areas including cell label-
ing, biosensing, in vivo imaging, bimodal magnetic-luminescent imaging, and diagnostics. We 
also explore toxicity issues surrounding these materials and speculate about the future uses of 
quantum dots in a clinical setting.
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Introduction
Colloidal quantum dots (QDs) have completed the transition from a once curious 
demonstration of quantum conﬁ  nement in semiconductors to ubiquitous ﬂ  uorophores 
providing unique insights in biological investigations (Alivisatos 2004; Medintz et al 
2005b; Michalet et al 2005). With well-established inorganic synthetic techniques now 
available for generating high quality QDs in solution, many experimentalists have 
focused on applications using these novel materials that exploit the numerous unique 
physical and optical properties of these luminescent nanoparticles. In 1998, two seminal 
papers appearing consecutively in an issue of Science provided the ﬁ  rst glimpse of 
the vast potential of quantum dots as probes for studying biology as well as a strong 
impetus for their rapid growth in such applications (Bruchez et al 1998; Chan and Nie 
1998). As we approach a decade since those initial reports, the current literature is rife 
with examples of quantum dots used in speciﬁ  c biological applications. This trend 
is directly attributable to the unique characteristics exhibited by these nanocrystals 
and related to considerable improvements in synthetic techniques. Although they are 
often portrayed simply as alternatives to organic dyes, QDs have many important 
distinguishing characteristics that are unlike those of molecular ﬂ  uorophores (Murray 
et al 2000). In particular, resistance to photobleaching is unparalleled in semiconductor 
nanoparticles allowing them to retain their luminescent properties for remarkably long 
periods under continuous illumination. Perhaps most widely known is the variation of 
QD optical properties with particle size (Figure 1a) which permits tunable absorption 
and emission spectra. QDs can also be synthesized to be effectively monodispersed, 
leading to exceptionally narrow emission spectra with desirable symmetric proﬁ  les (cf. 
Figure 1b). While these principal advantages of colloidal QDs have been known for 
many years, only recently has the ﬁ  eld matured to the extent that there is signiﬁ  cant 
practical use of these materials.
Biological applications require luminescent probes that remain stably dispersed in 
aqueous media over a wide range of pH and ionic strengths, and accordingly there has 
been substantial effort devoted to generating water-soluble nanocrystals. Early studies 
considered aqueous phase synthesis using inverse micelles which naturally produce International Journal of Nanomedicine 2008:3(2) 152
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Figure 1 Comparison of Rhodamine Red (RR) and DsRed2 spectra to those of representative samples of QDs. Multiple QD emission spectra ﬁ  t within the same spectral 
window as that of an organic or genetically encoded dye. (a) Absorption and emission of xis6 different QD populations. The black line shows the absorption of the 510 nm 
emitting QDs. (b) Absorption and emission of RR, a common organic dye, and genetically encoded DsRed2 protein (Baird et al 2000). (c) Color photo demonstrating the 
size-tunable ﬂ  uorescence properties and spectral range of the six QD dispersions plotted in (a) versus average CdSe core size. All samples were excited at 365 nm with a UV 
lamp. For the 610 nm emitting QDs, this demonstrates an effective Stokes shift of about 250 nm. (d) Comparison of QD size to a maltose binding protein (MBP) molecule. 
555 nm  emitting CdSe-ZnS core-shell QDs, diameter ∼60 Å, surface functionalized with dihydrolipoic acid (red shell ∼9–11 Å) has a diameter ∼78–82 Å. Diagram depicts 
the homogeneous orientation MBP assumes relative to the QD (Copyright © 2004 National Academy of Sciences USA) (Medintz et al 2004). MBP is a midsize protein 
(Mr ∼44 kDa) with dimensions of 30 × 40 × 65 Å (Medintz et al 2003). Source: Medintz IL, Uyeda HT, et al 2005. Quantum dot bioconjugates for imaging, labeling, and sensing. 
Nature Materials 4:435–46. Reproduced with permission.International Journal of Nanomedicine 2008:3(2) 153
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water-soluble QDs, however these methods have generally 
produced lower quality materials than methods using organic 
coordinating solvents (Kortan et al 1990). Fortunately, there 
are now numerous effective methods available for creating 
hydrophilic QDs post-synthesis which can be divided into 
two main categories: complete cap exchange or native sur-
face modiﬁ  cation. The former involves the displacement of 
hydrophobic ligands with hydrophilic moieties that coordi-
nate with surface atoms in the outermost shell layer. In the 
case of CdSe-ZnS QDs, this usually entails replacing alkyl 
amines, phosphines, and other surface active ligands with 
thiols covalently linked to hydrophilic groups (Figure 2). 
Mono and dithiol groups have been shown to stably bind QDs 
with ZnS shells (Chan and Nie 1998; Mattoussi et al 2000). 
In select cases, these modiﬁ  ed materials are stable in aque-
ous media for months to a year (or more) without signiﬁ  cant 
aggregation or loss of function (Uyeda et al 2005). The lat-
ter method retains the native hydrophobic capping ligands, 
however an amphiphilic molecule (such as a phospholipid) 
is introduced that favorably associates with the hydrophobic 
alkyl chains while simultaneously exposing a hydrophilic 
group to the aqueous solvent (Dubertret et al 2002). This 
has the advantage of retaining the exceptional passivating 
features of the native hydrophobic ligands (eg, alkyl phos-
phines) and has to this point been the preferred procedure 
for commercially-produced biocompatible QDs.
QD bioconjugates merge the speciﬁ  c biological function 
of molecules such as DNA, proteins, and peptides with the 
novel photophysical properties of luminescent inorganic 
nanocrystals (Figure 1d). These hybrid nanomaterials are 
possible largely due to the solubilization methods described 
previously which allow biomolecules to remain stable and 
functional following assembly to nanoparticles. Traditional 
ﬂ  uorescence methods (using organic dyes or rare earth 
metal chelates) have revolutionized many clinical methods 
and procedures such as diagnostic assays. Similarly, QDs 
have considerable potential to further improve existing 
methods and inspire entirely new diagnostic strategies due 
to their extraordinary photophysical properties. This review 
discusses some of the present clinical applications of lumi-
nescent quantum dots and explores their future prospects 
in this area.
Cell labeling
One of the broadest uses of ﬂ  uorescent probes in biology is the 
labeling of cellular structures. Naturally, the earliest demon-
strated uses of QDs in biology were to label cells with a new 
class of bright and stable ﬂ  uorophores. Multicolor labeling 
of cells is a powerful technique for visualizing many of these 
structures simultaneously, such as cytoskeletal proteins or 
organelles, and to elucidate intracellular processes. Although 
cell labeling with organic dyes has been commonplace for 
decades, using multiple labels simultaneously remains a 
cumbersome procedure due to the narrow absorption proﬁ  les 
of most dyes. Effective multicolor labeling requires an assort-
ment of ﬁ  lters to properly excite and collect ﬂ  uorescence 
from speciﬁ  c dye molecules. Moreover, if laser excitation 
is used, multiple sources are typically required to excite all 
of the dyes labeling the cell which can be expensive and 
requires a complex microscopy arrangement speciﬁ  c to the 
experiment. The continuous excitation of dyes inevitably 
results in signiﬁ  cant photobleaching that quenches the lumi-
nescence over short time scales (seconds to minutes). This 
severely limits the practical observation time for a sample, 
even with the addition of various anti-bleaching chemical 
agents (Lakowicz 1999).
By contrast, QDs are excellent ﬂ  uorescent probes for 
long-term multicolor cell labeling. Due to their exceptionally 
broad absorption proﬁ  les (Figure 1a), they can be efﬁ  ciently 
excited at any wavelength smaller than their initial band edge 
absorption. As the excitation photon energy increases (and 
wavelength decreases), the QD absorption likewise increases 
suggesting that extremely large effective Stokes shifts (spec-
tral intervals between excitation and emission maxima) are 
possible (Leatherdale et al 2002). The effective brightness 
per probe particle is also superior with quantum dots as evi-
denced by their large molar absorption cross-sections which 
are a consequence of their nanometer size and composition. 
Perhaps the most impressive feature of QDs is their resis-
tance to photobleaching which is quantitatively orders of 
magnitude superior to common organic dyes. Occasionally, 
QDs can even demonstrate photo-induced brightening where 
the luminescence quantum yield (QY) noticeably increases 
under continuous excitation possibly due to annealing of 
their surfaces. Multiplexed emission is also more spectrally 
isolated with QDs due to narrow and symmetric ﬂ  uorescence 
proﬁ  les (routinely 40 nm full-width at half-maximum) 
which reduces signal crosstalk and increases the number of 
labels than can be used simultaneously in a single system 
(Dabbousi et al 1997). This is especially useful in quantitative 
ﬂ  uorescence studies where spectral deconvolution is required 
to monitor individual signal channels (De Rosa et al 2001).
Beginning with the ﬁ  rst successful demonstrations of QD 
cell labeling by the Alivisatos and Nie groups, QDs have 
been widely used as luminescent cell markers that identify 
molecular structures. However, overcoming the challenge International Journal of Nanomedicine 2008:3(2) 154
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Figure 2 Examples of surface ligands used to produce water soluble nanocrystals. Following synthesis, the hydrophobic coordinating ligands in (a) can be replaced with hydrophilic 
moieties through a cap exchange process. Some possibilities include: (b) mercapto n-alkyl acids (MnA; eg, mercaptoacetic acid, MAA) (Chan and Nie 1998), (c) dithiothreitol 
(DTT) (Pathak et al 2001), (d) dihydrolipoic acid (DHLA) (Mattoussi et al 2000), (e) peptides containing appropriate high afﬁ  nity residues (e.g, Cys – C and His – H) (Pinaud 
et al 2004), (f) trishydroxypropyl phosphine (THPP) (Kim and Bawendi 2003), (g) dihydrolipoic acid-polyethylene oxide (DHLA-PEG) (Uyeda et al 2005), (h) dendrons (Guo 
et al 2003). Many of these can be processed further to crosslink the ligands, add new functional groups, and/or attach biomolecules (QD/ligands not drawn to scale).
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of creating stable, water-soluble materials that could be 
delivered within cells was formidable. Two unique strategies 
were ultimately used to achieve a similar goal. Bruchez and 
colleagues (1998) used phalloidin to speciﬁ  cally target actin 
ﬁ  laments, followed by exposure to streptavidin and biotinyl-
ated QDs to form a sandwich structure. Electrostatically-
charged QDs bearing trimethoxysilylpropyl urea and acetate 
groups were shown to label the nucleus. Alternatively, Chan 
and Nie (1998) demonstrated transferrin-mediated endocytic 
uptake of QDs within HeLa cells which resulted in efﬁ  cient 
and preferential delivery of transferrin-labeled QDs versus 
unlabeled QDs. These early studies proved that QDs could 
perform similar to organic dye ﬂ  uorophores within cells and 
provided initial guidance regarding successful strategies for 
efﬁ  cient cell delivery.
Many examples have since followed where QDs have 
been used to label cellular structures both within and exter-
nal to the cell membrane. Using conventional methods, 
QDs have been delivered inside cells via receptor-mediated 
pathways where speciﬁ  c ligands were attached to QDs to 
induce cellular uptake, as well as nonspeciﬁ  c endocytosis 
(ie, pinocytosis) where cells were incubated with a 
concentrated QD solution (Jaiswal et al 2003). Delivery 
of QDs via endocytosis has inherent beneﬁ  ts because it 
invokes native cellular mechanisms to transfer nanoparticles 
across the cell membrane. It is consequently thought to be 
the least disruptive delivery method as well as the most 
versatile. QDs capped with compact carboxylated ligands 
have shown reasonable rates of nonspeciﬁ  c endocytosis 
(Jaiswal et al 2003), however receptor-mediated uptake 
has demonstrated better efﬁ  ciency by speciﬁ  cally target-
ing receptors displayed on the cell surface (Chan and Nie 
1998; Lidke et al 2004; Bharali et al 2005). As expected, 
ligands previously identiﬁ  ed to cue and facilitate receptor-
mediated endocytosis continue to function effectively when 
attached to QD surfaces resulting in efﬁ  cient delivery of 
the modiﬁ  ed nanoparticle assembly within cells, but with 
the potential drawback of the cargoes remaining largely 
conﬁ  ned inside the endosomes (Delehanty et al 2006). If 
the intended destination of a QD bioconjugate is a speciﬁ  c 
organelle or general release into the cytosol, this perpetual 
conﬁ  nement presents a signiﬁ  cant obstacle.
Alternative delivery methods that introduce microscopic 
mechanical defects in the cell membrane are also options 
for inserting nanoparticle cargoes, but with an elevated 
risk of traumatizing the cell which may compromise long 
term viability and perturb normal function. Electroporation 
and microcapillary injection have been used to introduce 
nanoparticles into live cells with varying success (Dubertret 
et al 2002; Derfus et al 2004a; Uyeda et al 2005). In par-
ticular, microcapillary injection is suitable for introducing 
well-dispersed QD bioconjugates directly into the cytosol 
which could be desirable for certain sensing applications. 
However, the serial nature of this method is time-consuming 
and therefore considerably limits the number of cells that can 
be labeled in a practical period and subsequently isolated. 
Other methods including ballistic delivery and scrape loading 
are also possibilities, but have not been widely reported.
With the availability of commercial labeling kits, the 
prevalence of QDs in cell labeling applications has increased 
dramatically. Despite their popularity and success, com-
mercial materials currently have somewhat limited potential 
due to the use of speciﬁ  c proprietary coatings and surface 
ligands to passivate and stabilize the nanoparticles. Similar 
to the challenges encountered in gene therapy applications, 
given the complexity of targeted delivery and function 
within cells it is likely that more ﬂ  exible and customized QD 
systems will be required for long-term intracellular imaging 
applications.
Biosensing and energy transfer
Due to their unique physical and optical properties, colloidal 
QDs have been used to develop new methods of biosensing. 
By attaching biomolecules to the QD surface, it is possible to 
generate complex bioconjugates that merge biological speci-
ﬁ  city and function with the desirable optical characteristics 
of QDs. In many cases the nanometer size of QDs allows 
the nanocrystal to become a central structural component 
that can accommodate numerous copies of a particular 
biomolecule (eg, protein or DNA) or several different bio-
molecules simultaneously; as a result, these bioconjugates 
are sometimes referred to as “nanosensors.” As robust 
ﬂ  uorophores, QDs are compatible with conventional bio-
sensing techniques that implement ﬂ  uorescence to produce 
a large measurable signal. Fluorescence resonance energy 
transfer (FRET) in particular has been a popular method of 
signal transduction due to its sensitivity to molecular scale 
interactions (Lakowicz 1999; Clapp et al 2004; Medintz 
et al 2004). An early FRET-based technique was demon-
strated by Patolsky and colleagues (2003) for the study of 
telomerization and DNA replication dynamics. Thiolated 
DNA was attached to the surface of water-soluble CdSe-ZnS 
QDs. In the presence of appropriate enzymes (telomerase or 
Klenow fragment) and dye-labeled nucleotides, the emis-
sion spectra showed a time dependent red-shift indicating 
efﬁ  cient energy transfer from QD to dye speciﬁ  cally due to International Journal of Nanomedicine 2008:3(2) 156
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telomerization or replication, respectively. The telomeriza-
tion results were corroborated with AFM images showing 
growth of DNA extending from the QD surface. The same 
group later looked at QD-based FRET for detecting DNA 
hybridization and cleavage (Gill et al 2005). They noted 
that full recovery of the ﬂ  uorescence emission following 
the addition of enzyme was not possible due to nonspeciﬁ  c 
interactions between the dyes and nanoparticles. This could 
be a signiﬁ  cant limitation in this particular arrangement, 
however nonspeciﬁ  c interactions might be reduced through 
unique surface passivation methods.
Medintz and colleagues (2003) used a related approach 
to develop a prototype FRET-based QD biosensor capable 
of detecting the nutrient sugar maltose in solution. Maltose 
binding protein (MBP), pre-bound to an analog sugar-dye 
complex, was conjugated to water-soluble QDs resulting in 
many MBP attached to each QD. In this initial state, ﬂ  uo-
rescence from the QD was signiﬁ  cantly quenched by the 
nonemissive dye. As maltose is added to solution, the analog 
sugar-dye complex is progressively displaced resulting in a 
substantial increase in ﬂ  uorescence signal with increasing 
concentration. A reagentless implementation of a maltose 
biosensor was also demonstrated where the QD transfers 
energy to a Cy3 dye covalently attached near the binding 
pocket of MBP (Medintz et al 2005a). Sensing is achieved 
by monitoring the Cy3 ﬂ  uorescence as a function of maltose 
concentration where the quantum yield of the dye varies due 
to differences in solvent interaction with the dye between the 
bound and unbound states.
In another demonstration of FRET-based biosensing, 
Medintz and colleagues (2006) developed QD-peptide 
bioconjugates designed to measure rates of enzymatic 
digestion. Peptides were synthesized to have domains 
speciﬁ  c for QD attachment, structural rigidity, protease 
recognition, and dye labeling. In a manner similar to the 
maltose biosensor, the intact QD bioconjugates exhibit 
quenched ﬂ  uorescence due to the proximity of the dye labels. 
However, as an appropriate enzyme is added to solution, 
some of the peptides are cleaved allowing the dyes to 
diffuse away from the QD surface resulting in an increased 
ﬂ  uorescence signal. By altering the recognition sequence 
(consisting of 2–4 carefully chosen amino acid residues), 
the biosensor can be tuned to respond to a speciﬁ  c enzyme. 
More recently, Shi and colleagues (2006) demonstrated 
a QD FRET-based probe for enzymatic activity using 
compact dye-labeled tetra-peptide ligands. The probe was 
able to detect increased metalloproteinase activity in the 
extracellular matrix surrounding cancerous breast cells. A 
very recent communication by Gill and colleagues (2006) 
reports a multifunctional enzymatic probe for tyrosinase and 
thrombin. The former is observed following the oxidation 
of tyrosine near the surface of a QD, and the latter by 
speciﬁ  c scission of a linker peptide which interrupts energy 
transfer.
An analogous signal transduction method using charge 
to modulate QD ﬂ  uorescence was demonstrated by Sandros 
and colleagues (2005) to detect maltose in solution. Similar 
to the FRET-based maltose biosensor described above, 
this method utilizes MBP to specifically recognize the 
disaccharide. However, in this system a Ru complex transfers 
charge to the nearby QD thus quenching ﬂ  uorescence when 
the protein is in an unbound/open conformation. As MBP 
binds maltose in solution, the hinge-bending movement of 
the protein positions the Ru complex sufﬁ  ciently far away 
from the QD surface to disrupt charge transfer and enable 
ﬂ  uorescence emission from the exciton. In a slightly differ-
ent conﬁ  guration, the same group developed a nanosensor 
selective for the fatty acid palmitate using QDs bound to 
intestinal fatty acid binding protein (Aryal and Benson 
2006). In this arrangement, it is thought that a solvent occu-
pancy effect, rather than a protein conformational change, 
is responsible for modulating the QD ﬂ  uorescence. In both 
systems where a Ru complex is conjugated to QDs via a 
protein, the sensing method appears to be general for many 
protein-ligand pairs where charge transfer is responsible for 
signal transduction; however, the exact mechanism has yet 
to be fully elucidated.
Collectively, the preceding methods demonstrate 
the versatility and functionality of QDs in ﬂ  uorescence 
biosensors. Energy transfer in these systems allows sensitive 
measurements of events such as binding, digestion, or 
conformational changes occurring on the molecular 
scale. Many of the beneﬁ  ts of QDs are unique and allow 
development of nanosensors that can retain their function 
over long periods and potentially in living tissue. Most of 
the reports in the literature are preliminary demonstrations, 
yet they offer a tantalizing preview of what is possible using 
QDs.
In vivo imaging
The ability to visualize native processes occurring in living 
organisms is invaluable for clinical diagnostic applications, 
yet remains elusive in practice due to conventional imaging 
limitations and the availability of suitable ﬂ  uorescence mark-
ers. Regarding the latter, many organic dyes have very short 
lifetimes (∼1 ns), are susceptible to photodegradation, and International Journal of Nanomedicine 2008:3(2) 157
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show inadequate ﬂ  uorescence brightness (Lakowicz 1999). 
Additionally, tissue autoﬂ  uorescence can exhibit similar 
spectroscopic characteristics making it difﬁ  cult to resolve 
the desired signal from unwanted background. Due to their 
unique photophysical properties, QDs are promising ﬂ  uoro-
phores for in vivo ﬂ  uorescence imaging and can overcome 
many of the usual limitations of dyes.
An early study by Akerman and colleagues (2002) exam-
ined targeted delivery of QDs to speciﬁ  c locations within live 
mice, however ﬂ  uorescence imaging was performed after the 
animal was sacriﬁ  ced and the tissue sectioned. Noninvasive, 
real-time in vivo ﬂ  uorescence imaging requires exciting 
ﬂ  uorophores and detecting their emission through tissue 
which is invariably hindered by scattering and absorption 
of both the excitation and emission wavelengths. Although 
CdSe-ZnS QDs are by far the most common choice for 
high quantum yield nanocrystals, their visible ﬂ  uorescence 
(restricted within a range from 470 to 650 nm) is not well-
suited for imaging through tissue. Nonetheless, Gao and 
colleagues (2004) showed that CdSe-ZnS QDs could be used 
to image human tumors implanted in mice by implementing 
an image processing algorithm to isolate signal contributions 
from QDs and autoﬂ  uorescence. However, their method was 
limited to imaging structures very near the surface due to the 
limited penetration depth of visible wavelengths. A similar 
study was reported by Ballou and colleagues (2004) where 
they used several imaging methods, including transmission 
electron microscopy, to explore long term QD partitioning 
in tissue.
Using a different semiconductor core material and 
specifying an appropriate nanocrystal size, QDs can be 
excited and observed in the near-infrared (near-IR or NIR) 
which coincides with a range of optical transparency for 
living tissue (Figure 3a) (Lim et al 2003). Due to their size 
and composition, QDs exhibit an unusually large molar 
extinction coefﬁ  cient which leads to improved absorption 
of photo-excitation and effective brightness. Size tuning 
can further optimize the peak emission wavelength for 
maximum ﬂ  uorescence penetration through relatively thick 
tissue  (1 cm). This concept was ﬁ  rst demonstrated by 
Kim and colleagues (2004) using so-called “Type II” QDs 
composed of core-shells with offset bandgaps. In this study, 
near-IR QDs were used to identify sentinel lymph nodes 
(directly invaded by metastatic cancer cells) in mice. Using 
a ﬁ  ltered halogen source and an IR camera, the collection 
of QDs within tissue was monitored in real-time to identify 
a region for surgical resection (Figure 4). The size of these 
nanocrystals (∼15–20 nm diameter) was shown to be ideal 
for their efﬁ  cient collection and retention in lymph nodes. 
This study demonstrates the feasibility of near-IR imaging 
for real-time surgical assistance, however the toxicity issues 
(to be discussed) associated with most QD materials remain 
a formidable hurdle to use in humans.
In vivo ﬂ  uorescence imaging has undoubtedly beneﬁ  ted 
from the development of QD ﬂ  uorophores where their 
unique properties allow more ﬂ  exible imaging strategies. 
For example, the expanded use of multi-photon microscopy 
can provide a more efﬁ  cient method of exciting QDs in 
vivo. This is due to the exceptional multi-photon absorption 
cross-section of semiconductor nanocrystals (Larson et al 
2003). In certain cases, the effective brightness of QD 
ﬂ  uorophores is two or more orders of magnitude higher 
than organic dyes using multi-photon excitation. By 
preferentially exciting ﬂ  uorophores very near the highly 
focused excitation beam, high-resolution fluorescence 
images can be generated while eliminating out-of-focus and 
autoﬂ  uorescence contributions. This method has yet to be 
fully realized, however. Other in vivo imaging modalities 
such as magnetic resonance imaging (MRI) and positron 
emission tomography (PET) could also beneﬁ  t from QDs 
(Michalet et al 2005).
Diagnostics
One medical area where QDs may have signiﬁ  cant impact 
is in diagnostics and clinical assays. The unique properties 
of QDs have been investigated almost exclusively for two 
techniques that require the use of diagnostic ﬂ  uorophores: 
immunolabeling and nucleic acid detection. As QDs are a 
relatively new class of materials, the focus has been primarily 
on proof-of-concept demonstrations with various bioconjuga-
tion approaches being tested.
Immunolabeling
For the purposes of this review, we deﬁ  ne immunolabeling 
loosely as the use of antibody-driven speciﬁ  c binding to a 
target protein or biomolecule and the visualization of this 
event with some form of QD labeling. Table 1 presents a 
semi-comprehensive list where QDs and immunolabeling 
have been used for mostly proof-of-concept diagnostic 
purposes.
Many of the reported examples target the detection of 
various cancer markers within cells including c-Abl, CA-
125, p-glycoprotein, mortalin, cytokeratin, prostate speciﬁ  c 
membrane antigen, and carcinoembryonic antigen (see 
Table 1). These markers are associated with transformation 
or metastasis and are usually indicative of both the cancer International Journal of Nanomedicine 2008:3(2) 158
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and its progression and are thus of pathological interest. 
Other uses include intracellular viral monitoring, blood 
cell antigen typing, visualizing drug therapy effects on 
cellular metabolism, and monitoring of cell markers. The 
only prominent nonimmunological exception is an example 
where the metastatic potential of cell lines was shown to 
correlate well with their ability to take up QDs from culture 
wells during migration (Parak et al 2002). However, this is 
more of a scientiﬁ  c curiosity and will likely never ﬁ  nd use 
as a prognostic indicator.
For almost half of the examples cited in Table 1, 
commercially available QDs (Quantum Dot Corporation/
Invitrogen) have been used which are either purchased 
pre-coated with streptavidin (for conjugation with bioti-
nylated antibodies) or some type of species-speciﬁ  c IgG. 
This suggests that for many of these immunolabeling uses, 
commercial QD materials may be adequate and thus obviate 
the need to synthesize, solubilize, and functionalize custom 
materials. The greatest potential of QDs in this area is 
“multiplexing” or the simultaneous detection of multiple 
targets, since multiple colors of QDs can be excited with 
a single wavelength far removed from their respective 
emissions (Figure 3b). Indeed, examples have been reported 
of simultaneous cellular labeling with up to ﬁ  ve QD colors 
(Medintz et al 2005b). In terms of pathology and diagnosis, 
this would enable the colocalization of many markers within 
the same cells/tissues and allow determination of their spatial 
distribution. Based on the typical emission spectra of QDs, 
it is reasonable to anticipate ten or more colors of QDs (or 
QDs and dyes) could be used simultaneously. Furthermore, 
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Figure 3 (a) Emission maxima and sizes of quantum dots of different composition. Quantum dots can be synthesized from various types of semiconductor materials (II-VI: CdS, 
CdSe, CdTe; III-V: InP, InAs.; IV-VI: PbSe) characterized by different bulk band gap energies. The curves represent experimental data from the literature on the dependence of peak 
emission wavelength on QD diameter. The range of emission wavelength is 400 to 1350 nm, with size varying from 2.0 to 9.5 nm (excluding the organic passivation/solubilization 
layer). All spectra are typically around 30 to 50 nm (full width at half maximum). Inset: Representative emission spectra for some materials. Data for CdHgTe-ZnS have been 
extrapolated to the maximum emission wavelength obtained in the Weiss group. (b) Absorption (upper curves) and emission (lower curves) spectra of four CdSe-ZnS QD 
samples. The blue vertical line indicates the 488 nm line of an argon-ion laser, which can be used to efﬁ  ciently excite all four types of QD simultaneously. (c) Size comparison 
of QDs and comparable probes/biomolecules. FITC, ﬂ  uorescein isothiocyanate; GFP, green ﬂ  uorescent protein; QD, green (4 nm, top) and red (6.5 nm, bottom) CdSe-ZnS QD; 
qrod, rod-shaped QD (sizes reported on Invitrogen’s web site). Three proteins – streptavidin (SAV), maltose binding protein (MBP), and immunoglobulin G (IgG) – have been 
used for further functionalization of QDs and add to the ﬁ  nal size of the QD, in conjunction with the solubilization chemistry. Copyright © 2005 AAAS. Michalet X, Pinaud FF, 
et al 2005. Quantum dots for live cells, in vivo imaging, and diagnostics. Science, 307:538–44. Reproduced with permission.International Journal of Nanomedicine 2008:3(2) 159
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if a UV excitation source is used in combination with more 
red-emitting QDs (approaching the near-IR), brighter signals 
can be achieved as the molar extinction coefﬁ  cients of these 
materials increases signiﬁ  cantly towards the UV. However, 
the limiting barrier is bioconjugation. Streptavidin-coated 
QDs will bind any biotinylated molecule indiscriminately 
and thus each “color” or antibody-labeled QD must either 
be prepared separately or a different and speciﬁ  c attachment 
scheme must be found for each combination of antibody and 
QD. For example the use of anti-mouse IgG coated QDs 
(targeting mouse-derived antibodies) in combination with 
anti-goat IgG coated QDs (targeting goat-derived antibodies) 
and streptavidin coated QDs, etc. This is not easily accom-
plished as there are currently a limited number of such QD 
coatings available, and this will be further complicated by 
the choice of speciﬁ  c antibody for a particular experiment. 
Although antibody cross-reactivity is a serious issue that 
can further limit any potential “multiplexed” immunological 
assays, Goldman and colleagues (2004) were still able to 
demonstrate four-color simultaneous small molecule toxin 
detection using a commercial plate reader and one excita-
tion wavelength. Although not in vivo diagnostics per se, 
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Figure 4 NIR QD imaging in vivo. Images showing the surgical ﬁ  eld of a pig injected intradermally with 400 pmol of NIR QDs in the right groin. Four time points are shown 
from top to bottom: before injection (autoﬂ  uorescence), 30 s after injection, 4 min after injection and during image-guided resection. For each time point, color video (left), 
NIR ﬂ  uorescence (middle) and color-NIR merge (right) images are shown. Note the lymphatic vessel draining to the sentinel node from the injection site. Copyright © 2004 
Nature Publishing Group. Kim S, Lim YT, Soltesz EG, et al 2004. Near-infrared ﬂ  uorescent type II quantum dots for sentinel lymph node mapping. Nature Biotechnology 22:93–7. 
Reproduced with permission.International Journal of Nanomedicine 2008:3(2) 160
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this did demonstrate the strong potential of QD usage in 
combination with antibodies.
Nucleic acid detection
From a diagnostic standpoint, QDs have been used in this 
area primarily as a visualization tool for nucleic acid array 
detection, in homogenous mutation assays, or as the ﬂ  uoro-
phore in ﬂ  uorescence in situ hybridization (FISH). Again, 
this work has been largely “proof of concept” with several 
different bioconjugation strategies tested. For nucleic acid 
arrays, the majority of studies have attempted to combine 
the ability to multiplex with the increased sensitivity derived 
from QD photostability to improve detection and reduce both 
the sample and probe concentrations required. Gerion and 
coworkers demonstrated single nucleotide polymorphism 
(SNP) of p53 tumor suppressor gene mutations and multial-
lele detection of hepatitis B and C virus genes with a com-
mercial scanner and two colors of QDs (Gerion et al 2003). 
In a strong demonstration of QD potential for multiplexed 
analysis, Shepard accomplished a simultaneous “eight-plex” 
Table 1 Diagnostic related uses of quantum dots
Target/biomarker Tissue/cell type Labeling conﬁ  guration Comment Ref
Respiratory syncytial virus HEp-2 cells Commercial 
streptavidin-coated QDs
Track intracellular viral 
proteins 
(Bentzen et al 2005)
Red blood cell antigens Erythrocytes Glutaraldehyde functionalized 
QDs bound to monoclonal 
anti-A
Monitor A-antigens (de Farias et al 2005)
c-Abl proteins K-562 leukemia cells Uncapped CdSe QDs; broad 
white emission
Western blot and ﬂ  ow 
cytometry analysis
(Zhelev et al 2006)
Biotinylated cholera toxin Plasma membrane of 
neurons
Avidin-coated QDs Indirect staining of GM1 
gangliosides
(Jaiswal et al 2004)
B- and T-cell antigens Fixed lymph nodes Commercial IgG-coated QDs Simultaneous detection (Zahavy et al 2005)
p-glycoprotein Breast adenocarcinoma 
cells
QDs immobilized within 
polymeric beads
Monitor multidrug resistance 
phenotype
(Stsiapura et al 2004)
CA-125 tumor marker Ovarian cells Commercial streptavidin-
coated QDs
Monitor ovarian carcinoma (Wang et al 2004)
PMP70 peroxisomal 
membrane proteins
Liver cells Commercial streptavidin-
coated QDs
Monitor hypolipidemic drug 
therapy
(Colton et al 2004)
Metastatic potential Human mammary epithelial 
tumor cells
SiO2-capped CdSe QDs Correlated uptake of QDs 
during cellular migration with 
cells metastatic potential
(Parak et al 2002)
Band 3 protein Human erythrocytes Commercial antibody-coated 
QDs
Could monitor invasion of 
a malaria parasite
(Tokumasu and 
Dvorak 2003)
Mortalin Human  fetal  ﬁ  broblasts Commercial 
streptavidin-coated QDs
Monitor differential staining 
in cancer
(Kaul et al 2003)
p-glycoprotein/cytokeratin Breast adenocarcinoma 
cells/skin basal carcinoma
Polyallylamine coated QDs; 
Antibody attached via EDC 
chemistry
Demonstrated superior 
photostability for QDs
(Sukhanova et al 2004)
HER2 cancer marker Breast cancer cells Commercial streptavidin and 
IgG linked QDs
Labeled in both live and ﬁ  xed 
cells
(Wu et al 2003)
Epidermal growth factor 
(EGF) receptor
Breast cancer cells CdTe QD-coated magnetic 
polystyrene nanospheres 
coated with EGF
Labeling and magnetic 
separation
(Chu et al 2006a)
Carcinoembryonic antigen Human colon carcinoma 
cells
PEG modiﬁ  ed CdTe QDs Antibodies noncovalently 
associated with the QDs
(Hu et al 2006)
Prostate speciﬁ  c membrane 
antigen (PSMA)
Prostate tumor cells Commercial streptavidin-
coated QDs with biotinylated 
aptamers speciﬁ  c for PSMA
PSMA detected in both ﬁ  xed 
and live cells
(Chu et al 2006b)
CD36 Human monocytic cells 
and atherosclerotic tissue 
sections
Commercial QDs Flow cytometry and confocal 
microscopic analysis 
(Kahn et al 2006)
CD4/CD8 ratio Peripheral blood Commercial QDs Automated microscopy with 
four-color labeling
(Bocsi et al 2006)
Abbreviations: EDC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride; PEG, polyethylene glycol; QD, quantum dots.International Journal of Nanomedicine 2008:3(2) 161
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array consisting of both QDs and commercial cyanine dyes 
for co-detection of Bacillus anthracis genes (Shepard 2006). 
A number of other groups have also used Qbeads or QDs 
embedded in microspheres to simplify the sample handling, 
expand the number of available colors by using codes consist-
ing of QD mixtures in each bead, and increase the relative 
number of QDs hybridized per spot and hence the signal. Xu 
and colleagues (2003) focused on using such Qbeads for SNP 
typing while Eastman and colleagues (2006) demonstrated 
improved sensitivity in gene expression arrays.
Homogenous mutation assays based on two-color 
ﬂ  uorescence coincidence analysis have also been reported 
(Zhang et al 2005; Yeh et al 2006; Zhang and Johnson 2006). 
This method labels the target and the probe with different 
QDs, or QD-dye combinations and then detects the presence 
of both by their coincidence in a small focal volume. FRET 
conﬁ  gurations of QDs and dyes have also been used in this 
type of analysis (Zhang et al 2005). The principal beneﬁ  t 
of this format is that it can have single molecule sensitivity 
obviating the need for sample or signal ampliﬁ  cation. In 
QD-based FISH analysis, the focus has been to show that 
QDs could be superior to conventional ﬂ  uorophores due to 
increased photostability and the ability to multiplex or both. 
Xiao and Barker demonstrated increased photostability of 
QD based probes versus conventional dyes for the probing 
of human metaphase chromosomes (see Figure 5). Chan 
and colleagues, and Bentolila and Weiss also demonstrated 
increased sensitivity and the ability to multiplex in these 
assay formats (Chan et al 2005; Bentolila and Weiss 2006). 
These results indicate that the relatively large QD-DNA probe 
complexes can still penetrate the tight cellular and chromo-
somal structures while retaining hybridization speciﬁ  city. 
In contrast to the bioconjugation issues mentioned above 
for immunolabeling, the use of streptavidin QDs coupled to 
biotinylated DNA appears to sufﬁ  ce for this type of analysis. 
However, several groups have commented on the need for 
long linkers between the DNA probe portion and the QD 
(Bakalova et al 2005; Chan et al 2005). It is not unreasonable 
to expect more studies using FISH analysis with QDs in the 
near future as researchers become increasingly interested in 
multiplexing simpliﬁ  ed optical detection schemes.
Toxicity
The issue of QD toxicity presents perhaps the most serious 
obstacle to a full exploration of their in vivo usage in biomedi-
cal imaging. The toxicity arises primarily from two sources: 
1. the semiconductor materials that commonly constitute the 
QD core (and sometimes the overcoating shell) which can 
leach under certain circumstances (Derfus et al 2004b), and 
2. the generation of reactive and free radical species during 
excitation (Bakalova et al 2004a, 2004b). The toxicity of 
metals such as Cd and Se is well documented (Colvin 2003; 
Hoet et al 2004; Hardman 2006; Nel et al 2006). These heavy 
metals can cross the blood-brain barrier, can accumulate in 
adipose tissue with biological excretion half-lives greater 
than ten years, are primarily toxic to the liver and kidneys, and 
are considered possible teratogens and probable carcinogens 
(Colvin 2003; Hoet et al 2004; Hardman 2006; Nel et al 
2006). In addition to this direct toxicity source, the unique 
QD nanoscale structure presents a complex set of physio-
chemical characteristics that further compounds any simple 
studies or conclusions in this area. As detailed previously, 
the nanocrystalline cores can be constituted from different 
combinations of binary semiconductors such as CdSe, CdTe, 
CdS, and InP. Further, the cores are commonly encapsulated 
with a secondary semiconductor material and are then func-
tionalized with a variety of surface coating ligands including 
small thiolated molecules or larger amphiphilic polymers for 
aqueous compatibility (Medintz et al 2005b; Michalet et al 
2005). Additionally, even though the physical dimensions 
are on the nanoscale, the QDs can have a wide range of sizes 
with diameters ranging from 2 nm to greater than 10 nm; 
the latter is beyond the size limit that is passively excreted by 
the kidneys (Hoet et al 2004; Michalet et al 2005; Hardman 
2006; Nel et al 2006). For biological use, QDs can be further 
modiﬁ  ed with either proteins, such as NeutrAvidin, or other 
biomolecules such as DNA. Cumulatively, this combination 
of materials and physical properties serves to confound any 
systematic study of toxicity, even before issues such as dos-
age or exposure time are formally addressed. Nevertheless, a 
body of literature is slowly accumulating that is contributing 
to our understanding of this important issue.
Although much of the early research in this area was 
collected piecemeal, a number of excellent review articles 
have been published that summarize much of what is known 
in this area. Hoet and colleagues (2004) reviewed most of 
the data available up until 2004 on the health effects of 
nanoparticles. The authors point out that upon casual expo-
sure, nanoparticles would enter the body mainly via the lungs 
and intestines and to a lesser extent the skin. These routes are 
primarily attributable to the small size of the materials. Hard-
man (2006) has recently authored one of the most extensive 
reviews on the toxicity of semiconductor QDs in which the 
cumulative results from almost all previous in vivo studies 
(both cellular and small animal) are summarized. This study 
pays particular attention to the effects of different core-shell International Journal of Nanomedicine 2008:3(2) 162
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Figure 5 Speciﬁ  city of ﬂ  uorophore – streptavidin detection of biotinylated total human DNA probe in metaphase chromosomes and photostability (Mulder et al 2006). 
(a) Control (no ﬂ  uorophore – streptavidin conjugate); (b) streptavidin – Qdot 605 detection of chromosome 1q12 region (vertical and horizontal arrows); (c) Texas 
Red – streptavidin detection of biotinylated DNA hybridized to 1q12 (vertical arrows) and (d) FITC – streptavidin detection of 1q12 sites (vertical arrows). Bar in panel 
(c) is 10 µm. (e) Signal decay upon continuous illumination with ﬂ  uorescence microscope/mercury illumination in metaphase chromosome band 1q12 during 2 h continuous 
illumination. Red is Qdot 605, green is Texas Red, and blue is FITC. (f) Total intensity of whole interphase nuclei during 120 ms illumination (blue bars) and background (red 
bars). N = 3 cells in each. Copyright © 2004 Oxford University Press. Xiao Y, Barker PE. 2004. Semiconductor nanocrystal probes for human metaphase chromosomes. Nucleic 
Acids Research, 32:e28. Reproduced with permission.International Journal of Nanomedicine 2008:3(2) 163
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materials and their solubilizing ligands. The results that 
are summarized in these reviews reﬂ  ect publications that 
are primarily observational where the authors have reported 
the effects of a given QD material on a particular cell line or 
animal, at some speciﬁ  ed concentration(s) for some exposure 
time (Hoet et al 2004; Hardman 2006). In general, the results 
were mixed with some reporting no visible toxicity (Jaiswal 
et al 2003) while others reported high cytotoxicity (Hoshino 
et al 2004). This can be interpreted to reﬂ  ect what is posited 
above: the choice of core-shell material and solubilizing 
cap in conjunction with dosage/exposure time will obscure 
any simple assessments of toxicity. It is also notable that 
most of the cell lines used in these studies were transformed 
(immortal and primarily derived from different cancers) and 
thus might not reﬂ  ect either true toxicity or even a normal 
cellular response.
Recently, several reports have appeared that have 
focused exclusively on QD toxicity with more systematic 
approaches. Chan’s group has reported on the distribution, 
sequestration, and clearance of mercaptoundecanoic acid 
(MUA) functionalized QDs in rats (Fischer et al 2006). 
They found that QDs coated with bovine serum albumin 
(BSA) are cleared more rapidly from serum than those 
coated with crosslinked lysine. Further, most of the BSA 
coated QDs (99%) are found in the liver after 90 minutes 
as compared to the lysine QDs (40%). This result reﬂ  ects, 
perhaps, one of the primary metabolic roles of endogenous 
serum albumin. Interestingly, these QDs were not excreted 
from the rats even after 10 days. In another study, Chen’s 
group undertook a global molecular and cellular response 
investigation of skin and lung ﬁ  broblast cell lines when 
exposed to QDs coated with crosslinked silane and 
polyethylene glycol (PEG) (Zhang et al 2006). The authors 
found negligible toxicity in these model cells and attribute 
this result to appropriate sequestration of the core-shell 
material and the biocompatibility of the surface-bound PEG. 
Mattoussi’s group has reported on the dosage effects of QDs 
on different cell lines (Delehanty et al 2006). They found 
that acute (1 hour) versus chronic (continuous) exposure and 
labeling of different concentrations of QDs to two cell lines 
resulted in a signiﬁ  cantly different impact on subsequent 
cellular viability. No toxicity was noted for acute exposure 
at all concentrations while chronic exposure manifested 
signiﬁ  cant toxicity and loss of viability with increasing 
concentration of materials.
More generally, it is important to reiterate that almost all 
synthetic precursor materials used to make semiconductor 
QDs are toxic. Some can be physically dangerous since they 
are pyrophoric, while others are only toxic upon ingestion or 
prolonged exposure (Medintz et al 2005b). Hardman provides 
some fascinating perspective on synthetic scales and dosage 
issues by pointing out that a 2 g synthesis of 100 nm diameter 
particles contains enough material to dose every human on 
earth with around 300,000 particles (Hardman 2006). This 
highlights the importance of proper laboratory procedures 
during synthesis and appropriate disposal practices as more 
QD materials are synthesized worldwide. Researchers 
interested in determining the toxicity of a particular QD (or 
other nanoparticle) are not without resources. Foreseeing 
a need in this area, the National Cancer Institute (NCI) in 
conjunction with several other US health agencies have 
established the Nanotechnology Characterization Laboratory 
(NCL) to perform preclinical efﬁ  cacy and toxicity testing 
of nanoparticles (http://ncl.cancer.gov/). As part of its 
services, the NCL will characterize nanoparticles’ physical 
attributes, their in vitro biological properties, and their in vivo 
compatibility. The time required to characterize a particular 
nanomaterial is anticipated to be around 18 months. The Center 
for Biological and Environmental Nanotechnology (CBEN), 
a National Science Foundation (NSF) funded Nanoscale 
Science and Engineering Center at Rice University, provides 
information and focuses research on the environmental 
impact and toxicity of a variety of nanomaterials including 
QDs (http://cohesion.rice.edu/centersandinst/cben/index.
cfm). The International Council on Nanotechnology (ICON), 
CBEN’s multi-stakeholder initiative, provides another 
valuable resource by maintaining a nanomaterial-speciﬁ  c 
Environmental, Health, and Safety Database that can be 
accessed by the public (http://icon.rice.edu/research.cfm). 
The continuing debate in this area mirrors that of the general 
debate on the long-term environmental and health effects of 
all nanoscale materials (Colvin 2003; Nel et al 2006).
Bimodal luminescent-magnetic 
quantum dots for imaging
As noted throughout, QDs are excellent deep tissue and 
in vivo imaging/contrast agents due to several key proper-
ties. Although this ﬁ  eld is still in its infancy, an application 
based on combining QD ﬂ  uorescent imaging with magnetic 
resonance imaging (MRI) to deliver superior contrast and 
possibly detailed three-dimensional in vivo images has 
already emerged. The bulk of the research in this area has 
focused on synthesis and characterization. A variety of 
strategies exist for creating such bimodal materials; these are 
highlighted in Figure 4. In a one example, Gu and colleagues 
were able to generate a nanocrystalline luminescent/magnetic International Journal of Nanomedicine 2008:3(2) 164
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Figure 6 Strategies for creating bifunctional luminescent-magnetic QD materials. (a) Schematic and TEM image of heterodimeric luminescent/magnetic CdS/FePt nanoparticles. 
Copyright © 2004 American Chemical Society. Gu H, Zheng R, et al 2004. Facile one-pot synthesis of bifunctional heterodimers of nanoparticles: A conjugate of quantum dot 
and mangetic nanoparticles. J Am Chem Soc 126:5664–5. Reproduced with permission. (b) Schematic of the synthesis and properties of Co/CdSe core/shell nanocomposite 
nanocrystals. Copyright © 2005 American Chemical Society. Kim H,  Achermann M, et al 2005. Synthesis and characterization of Co/CdSe core/shell nanocomposites: Bifunctional 
magnetic-optical nanocrystals. J Am Chem Soc 127:544–6. Reproduced with permission. (c) Schematic representation of the preparation of QDs with a paramagnetic micellar 
coating. Copyright © 2006 American Chemical Society. Mulder WJM., Koole R, et al 2006. Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. 
Nano Letters 6:1–6. Reproduced with permission. (d) Schematic drawing of the synthesis of chitosan nanobeads that encapsulate both semiconductor QDs and paramagnetic 
Gd-DTPA. Copyright © 2005 Wiley-VCH. Tan WB, Zhang Y. 2005. Multifunctional quantum-dot-based magnetic chitosan nanobeads. Adv Mater, 17:2375–80. Reproduced with 
permission.International Journal of Nanomedicine 2008:3(2) 165
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CdS/FePt heterodimer in a stepwise manner (Figure 6a; Gu 
et al 2004). Klimov’s group took a slightly different approach 
by growing a CdSe shell over a Co core (Figure 6b; Kim et al 
2005). Rather than using a direct synthesis route, Mulder 
and colleagues (2006) coated CdSe-ZnS core-shell QDs 
with a PEGylated phospholipid and a gadolinium diethylene 
triamine pentaacetate-bisstearylamide (Gd-DTPA-BSA) 
paramagnetic lipid (Figure 6c). Also bypassing a direct 
synthesis, Tan and Zhang (2005) encapsulated CdSe-ZnS 
core-shell QDs and paramagnetic Gd-DTPA chelates into 
chitosan nanobeads (Figure 6d). Most of these materials have 
only undergone initial testing to demonstrate that they still 
retain the parent materials’ native luminescent and magnetic 
properties as synthesized and after intracellular delivery. 
Some remaining issues before wide-spread implementation 
include low QD quantum yield and appropriate relaxivity. 
Despite this, we can expect the great interest in this area to 
drive the synthesis of a variety of related materials and will 
shortly begin to see reports of increasingly more detailed 
in vivo images that have been generated with these bimodal 
materials. Of particular interest will be the ability to combine 
these bimodal probes with tumor speciﬁ  c antibodies for 
in vivo delivery and targeting.
Future outlook
What can we expect for the future clinical applications 
of quantum dots? QDs are already having an impact 
in molecular pathology. Ventana Medical Systems 
(http://www.ventanadiscovery.com) has recently started 
marketing the QD Map family of products. These are 
immunohistochemistry reagent kits for automated slide 
processing and ﬂ  uorescent detection of ﬁ  xed specimens. The 
selling point of this product family mirrors the list of unique 
QD photophysical properties, namely photostability, single 
source excitation, narrow emission, multiplexing capabilities 
and high quantum yield. However, the lack of consistent 
and reproducible methods to conjugate many different 
biomolecules such as antibodies, protein markers, DNA 
and RNA to QDs in a systematic manner with control over 
their ratio, orientation, and avidity continues to hamper their 
further use in clinical diagnostics. As this ability to couple 
biological recognition agents to QDs slowly improves, we 
can expect more commercial products incorporating QDs 
for clinical, diagnostic, and research purposes. The ability to 
combine QD-based analysis into a multiplexed format, be it 
immunohistochemistry or in situ nucleic acid hybridization, 
will be particularly signiﬁ  cant and should dramatically 
increase throughput and engender deep multi-marker studies 
that analyze correlations between RNA-protein expression 
and disease state. For biomedical imaging, the unanswered 
questions and complexity of the QD toxicity issue means that 
they will almost exclusively be used for research purposes 
in cellular and animal models.
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